VRAX Stock Summary and Trading Ideas (Virax Biolabs Group Limited - | NASDAQ:VRAX)

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

Virax Biolabs Group Limited - trades on the NASDAQ stock market under the symbol VRAX.

As of August 28, 2026, VRAX stock price declined to $2.82 with 32,271 million shares trading.

VRAX has a beta of 2.66, meaning it tends to be more sensitive to market movements. VRAX has a correlation of 0.05 to the broad based SPY ETF.

VRAX has a market cap of $2.25 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, VRAX traded as high as $225.00 and as low as $2.50.

VRAX has underperformed the market in the last year with a price return of -81.7% while the SPY ETF gained +19.7%. VRAX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -46.7% and -1.4%, respectively, while the SPY returned +2.2% and -0.9%, respectively.

VRAX support price is $2.70 and resistance is $3.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRAX shares will trade within this expected range on the day.